Phenotype of Alcohol-Related Nutritional Sensory Neuronopathies and Comparison With Dysimmune and Paraneoplastic Forms (NNS-OH)
Sensory neuronopathies (SNNs) are rare disorders characterized by damage to sensory neurons in the dorsal root ganglia. They may have dysimmune, paraneoplastic, toxic, or genetic causes. Alcohol-related nutritional sensory neuronopathy has recently been described and may present acutely or subacutely with pain, mimicking dysimmune or paraneoplastic disease. Distinguishing these causes early may help guide appropriate management. This international, multicentre, retrospective observational cohort study will describe the initial and follow-up clinical and electrophysiological phenotype of acute/subacute alcohol-related nutritional SNN and compare it with dysimmune and paraneoplastic SNN. Data will be abstracted from existing medical records. The protocol anticipates approximately 75 participants with alcohol-related nutritional SNN, 50 with dysimmune SNN, and 20 with paraneoplastic SNN. No additional procedure is performed for research purposes and no direct benefit is expected for participants.
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Jean-Philippe CAMDESSANCHE, PUPH
- Telefonnummer: +33 04 77 12 78 05
- E-mail: j.philippe.camdessanche@chuse.fr
Studiesteder
-
-
-
Brest, Frankrig, 29200
- CHU de Brest
-
Kontakt:
- Jean-Baptiste NOURY
- Telefonnummer: +33 02 98 22 33 33
- E-mail: jean-baptiste.noury@chu-brest.fr
-
Grenoble, Frankrig, 38500
- CHU de Grenoble
-
Kontakt:
- Martial Mallaret
- Telefonnummer: +33 04 76 76 75 75
- E-mail: MMallaret1@chu-grenoble.fr
-
Lille, Frankrig, 59000
- CHU de Lille
-
Kontakt:
- Céline TARD, Dr
- Telefonnummer: +33 03 20 44 59 62
- E-mail: CELINE.TARD@CHRU-LILLE.FR
-
Limoges, Frankrig, 87000
- CHU de Limoges
-
Kontakt:
- Laurent MAGY
- Telefonnummer: +33 05 55 05 55 55
- E-mail: Laurent.Magy@chu-limoges.fr
-
Montpellier, Frankrig, 34090
- CHU de Montpellier
-
Kontakt:
- Guillaume TAIEB
- Telefonnummer: +33 04 67 33 67 33
- E-mail: g-taieb@chu-montpellier.fr
-
Nantes, Frankrig, 44093
- CHU de Nantes
-
Kontakt:
- Yann PEREON
- Telefonnummer: +33 02 40 08 33 33
- E-mail: Yann.Pereon@univ-nantes.fr
-
Reims, Frankrig, 51100
- CHU de REIMS
-
Kontakt:
- Maxime Kirchhofer, Dr
- Telefonnummer: +33 03 26 78 78 78.
- E-mail: mkirchhofer@chu-reims.fr
-
-
France
-
Bordeaux, France, Frankrig, 33000
- CHU de Bordeaux
-
Kontakt:
- Guilhem SOLE, Dr
- Telefonnummer: +33 05.56.79.56.79
- E-mail: guilhem.sole@chu-bordeaux.fr
-
Créteil, France, Frankrig, 94000
- CHU Henri-Mondor
-
Kontakt:
- Thierry GENDRE, Dr
- Telefonnummer: + 33 01 49 81 21 11
- E-mail: thierry.gendre@aphp.fr
-
Garches, France, Frankrig, 92380
- AP-HP Hôpital Raymond-Poincaré
-
Kontakt:
- Edouard BERLING, Dr
- Telefonnummer: + 33 01 47 10 79 00
- E-mail: edouard.berling@aphp.fr
-
Le Kremlin-Bicêtre, France, Frankrig, 94270
- CHU de Bicetre
-
Kontakt:
- Guillemette BEAUDONNET, Dr
- Telefonnummer: + 33 01 45 21 21 21
- E-mail: guillemette.beaudonnet@aphp.fr
-
Marseille, France, Frankrig, 13005
- AP-HM Hôpital de la Timone
-
Kontakt:
- Emilien DELMONT, Dr
- Telefonnummer: +33 04 91 38 56 65
- E-mail: Emilien.DELMONT@ap-hm.fr
-
Paris, France, Frankrig, 75013
- AP-HP Hôpital Pitié-Salpêtrière
-
Kontakt:
- Thierry MAISONOBE, Dr
- Telefonnummer: +33 01 42 16 00 00
- E-mail: thierry.maisonobe@aphp.fr
-
Saint-Etienne, France, Frankrig, 42055
- CHU de Saint-Etienne
-
Kontakt:
- Jean-Philippe CAMDESSANCHE, PUPH
- Telefonnummer: + 33 04 77 12 78 05
- E-mail: j.philippe.camdessanche@chuse.fr
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients monitored in a neurology department for their sensory neuropathies
Beskrivelse
Inclusion Criteria :
- Age ≥ 18 years.
- Probable sensory neuronopathy according to the diagnostic criteria of Camdessanché et al.
- Acute or subacute onset (0-6 months).
- One of the following aetiologies: Alcohol-related nutritional SNN: chronic alcohol misuse (>100 g/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded. The minimum work-up includes an immune laboratory assessment including serum anti-neuronal antibodies, lumbar puncture, and thoraco-abdominal imaging. Dysimmune SNN: associated with Sjögren's syndrome, lupus, primary biliary cholangitis, anti-FGFR3 antibodies, or anti-AGO antibodies. Paraneoplastic SNN: associated with anti-Hu or anti-CV2/CRMP5 antibodies.
Exclusion Criteria :
- Exposure to platinum salts before the onset of sensory neuronopathy.
- Known hereditary neuropathy.
- Patient under guardianship or curatorship (tutelle or curatelle).
- Patient objection to the use of their data for the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Alcohol-related nutritional sensory neuronopathy
Adults with probable acute/subacute SNN attributed to chronic alcohol misuse (>100 g ethanol/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded using the minimum work-up specified in the protocol. |
|
Dysimmune sensory neuronopathy
Adults with probable acute/subacute SNN attributed to Sjögren's syndrome, lupus, primary biliary cholangitis, or associated with anti-FGFR3 or anti-AGO antibodies. |
|
Paraneoplastic sensory neuronopathy
Adults with probable acute/subacute SNN associated with anti-Hu or anti-CV2/CRMP5 antibodies. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Demographic and disease onset characteristics
Tidsramme: from july 2006 to april 2027
|
Description of demographic characteristics and disease onset, including age at onset (years), mode of onset, and initial symptoms. Each variable will be reported individually, as available in the medical records. |
from july 2006 to april 2027
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Jean-Phillippe CAMDESSANCHE, PUPH, CHU de Saint-Etienne
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IRBN 154-2026/CHUSTE
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .